Alnylam Pharmaceuticals and The Medicines Company UK are facing a claim for declaratory relief over supplementary protection certificates requested by biotech company Silence Therapeutics.
Europe’s highest court has found that in parallel lawsuits dealing with an identical trademark, the first court must take priority over the second—but not in all cases.
Amneal Pharmaceuticals and Impax Laboratories have agreed to merge, in a deal the companies say will create the fifth largest generics drugs business in the US.
The Broad Institute of Harvard and MIT has signed a patent licensing deal with DuPont Pioneer to provide CRISPR/Cas9 technology to agricultural researchers and producers.
CPA Global has found that Sanofi files the most patents covering human gene therapy and also spends the most on them overall.
A US judge has said Allergan’s controversial patent licensing deal with a Native American tribe could spell the end for the inter partes review.
A patent counsel at Eli Lilly discussed a recent dispute pitting Amgen against Sanofi and Regeneron, saying an appeals court ruling was convoluted.
The House of Lords is hearing from companies and regulators today on issues including the government’s life sciences strategy and Brexit’s impact on the industry.
The Saint Regis Mohawk Tribe has launched a fierce defence of its patent licensing deal with Allergan, giving the Senate Judiciary Committee six main reasons which justify the agreement.
US pharmaceutical company Orexigen Therapeutics has won a patent infringement case against Actavis Laboratories after suing the company over weight loss pill Contrave (naltrexone HCl/bupropion HCl extended release).